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Background: Metabolic Syndrome (MetS) is based on the same individual components, but has received several
amendments to the original definition. In this study, we verified the prevalence of metabolic syndrome according
to different criteria, and the impact of each component on the diagnostic.
Methods: This cross-sectional study enrolled HIV infected patients from a HIV/AIDS reference Center in southern
Brazil. Metabolic syndrome was identified according to the National Cholesterol Education Program Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP-ATPIII), the International Diabetes
Federation (IDF) and the American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) criteria,
and using a standardized questionnaire and blood testing.
Results: A sample of 1240, out of 1295, HIV-infected patients was enrolled. Males were on average older, more
educated, and had shorter time since the HIV diagnosis. The population attributable risk (PAR) for waist
circumference explained 80% of the prevalence among men and women (AHA/NHLBI criteria). Triglycerides had the
highest impact on prevalence of metabolic syndrome according to all criteria, independently of age, skin color and
HAART use, among men.
Conclusions: In this large sample of HIV infected patients, the overall prevalence of metabolic syndrome, under
either classification, was noticeable and the AHA/NHLBI definition accounted for the highest prevalence.
Keywords: Metabolic syndrome, Population attributable risk, HIV/AIDS, NCEP-ATPIII, IDF, AHA/NHLBI, Waist
circumferenceBackground
Metabolic syndrome (MetS) comprises a set of aggre-
gated risk factors including hypertension, central obesity,
abnormal fasting glucose, and dyslipidemia which in-
crease the risk of cardiovascular disease [1-4] and type 2
diabetes mellitus [1-4]. Since the third report of the* Correspondence: scfuchs@terra.com.br
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on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (NCEP-ATPIII) several amend-
ments have been incorporated in a working definition of
MetS [5,6]. The International Diabetes Federation (IDF)
criteria are based on the same components, but adopted
racial/ethnic cutoffs for waist circumference. It have
included waist circumference (WC) as a prerequisite for
MetS and the treatment for previous conditions as
additional criteria of abnormality [4,7].
The revision of NCEP-ATPIII guideline in 2005 [6,8,9]
incorporated the treatment for previous disorders (hyperten-
sion, diabetes, dyslipidemia) and reduced the cutoff fortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cently, a consensus between representatives of the American
Heart Association/National Heart, Lung and Blood Institute
(AHA/NHLBI) and IDF presented the AHA/NHLBI def-
inition of metabolic syndrome [10]. Central obesity was
removed as a prerequisite, so any three risk factors, out of
five, make the diagnosis of MetS.
Changes in the thresholds of MetS components account
for differences in prevalence rates of this diagnosis, chan-
ging also the population attributable risk (PAR) of their
components. Prevalence of MetS have been investigated
for non-HIV-infected subjects [11,12], but are scarcely
reported for the HIV-infected population [13] or com-
pared to the general population [14]. In addition, some
components of MetS are particularly vulnerable to the
effect of highly active antiretroviral therapy (HAART)
[15,16], and it might be time-dependent. This study veri-
fied the prevalence of metabolic syndrome according to
the NCEP-ATPIII, IDF and the AHA/NHLBI criteria, and
investigated the PAR of each component on prevalence
rates among HIV-infected adults.
Material and methods
This cross-sectional study enrolled HIV infected patients,
aged 18 to 79 years, from a public health Center for AIDS
Care and Treatment in Porto Alegre, southern Brazil. This
hospital is one of three reference centers, which provide
HIV treatment for patients living in the metropolitan area,
other cities of the state or even from other states. A sys-
tematic consecutive sample of outpatients, attending to
the center at the time of data collection, with confirmed
HIV infection, was eligible. Those with mental retardation,
restriction of freedom or pregnant women were excluded.
The study was approved by the institutional review board
of the Hospital de Clínicas de Porto Alegre- Comissão de
Ética em Pesquisa, GPPG: 06-243, which is accredited by
the Office of Human Research Protections. All partici-
pants signed a consent form.
Studied variables
Metabolic syndrome according to the NCEP-ATPIII [9]
was identified for patients who had at least three out of
five components: increased waist circumference (WC;
men ≥102 cm and women ≥88 cm), triglycerides ≥150
mg/dL or specific treatment, low high-density lipoprotein
cholesterol (HDL-C) (men <40 mg/dL, women <50 mg/dL
or specific treatment), blood pressure ≥130/≥85 mmHg or
anti-hypertensive treatment, and fasting glucose >100 mg/dL,
or previous diagnosis of type 2 diabetes mellitus or anti-
diabetic treatment. The IDF criteria for MetS [4,7] were
based on abnormal WC, in addition to two or more com-
ponents as those used by the revised NCEP-ATP III [9].
The WC cutoffs vary by racial/ethnic group, but since there
are no specific cutoffs for Brazilians, we used thoserecommended by the IDF for South Asians (≥90 cm, for
men, and ≥80 cm, for women). The AHA/NHLBI defin-
ition [10] used the same criteria of the revised NCEP-ATP
III [9], but the country specific WC cutoff suggested by
the IDF [4,7]. For this study, we used those for South
Asians.
Potential confounding factors were also studied: gen-
der, age, skin color (self-assessed), years at school, time
since the diagnosis of HIV (reported by the patient and
confirmed in medical records), and the use of HAART
in the 12 months previous to the interview (recorded in
medical record).
Data collection
Patients were interviewed at their routine medical visits by
research assistants trained and certified to participate in
the study. A standardized questionnaire was used to collect
the data, which included questions pertaining to demo-
graphic, socioeconomic, and other characteristics, and
quality control for data gathering was carried out for a 10%
systematic random sample of the interviews. Variables
related with HIV infection, use of HAART were obtained
at the interview and confirmed with medical records.
Standardized assessments of blood pressure [17,18] were
conducted using a validated automatic device (OMRON
CP-705) [19], and the average of eight measurements in
two office visits was used to diagnose hypertension. Waist
circumference was measured with a flexible inelastic tape
placed on the midpoint between the lower rib margin and
the iliac crest in a perpendicular plane to the long axis of
the body, while the subject stood balanced on both feet,
approximately 20 cm apart, and with both arms hanging
freely [4,20].
A 12 hours fasting glucose and lipid profile were
requested for patients who had not been tested in the
last three months. Laboratory tests were performed
using standardized techniques [21-24].
Sample size and statistical analysis
The sample size calculation was based on estimated MetS
prevalence rates among patients exposed to HAART
(25%) and non-exposed (15%) [14], with 80% of power
and 0.05 significance level (two-tailed). A sample size of
510 patients would be necessary whether a ratio of 1:1 of
non-exposed to exposed to HAART were enrolled, in-
creasing to 741 patients for a ratio of 1:3.
Bivariate analyses were conducted stratified by gender,
and statistical significance was assessed by Pearson chi-
square test or analysis of variance, using the Statistical
Package for the Social Sciences (SPSS Inc., version 16.0
Chicago, Il, USA). The Interactive Risk Attributable Pro-
gram (IRAP, version 2.2.0, National Cancer Institute,
Bethesda, MD, USA) software [25,26] was used to calcu-
late the PAR and corresponding 95% confidence intervals
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exposures and potential confounders. The PAR allows es-
timating the proportion of disease burden causally
explained by the components of the MetS [27].
Results
A sample of 1240, out of 1295, HIV-infected patients
was enrolled, 15 refused to participate and 40 fulfilled
the exclusion criteria. Table 1 shows that participants
were aged 38.6 ±10.1 years and mostly were whites.
Males were on average older, completed more years at
school, and the length of time since the HIV diagnosis
was longer than for women. The use of protease inhibi-
tors, on the other side, was more frequent among
women.
Table 2 shows that the waist circumference (IDF defin-
ition), triglycerides, and HDL-C levels were the most
prevalent components. All components levels, but fast-
ing glucose, were significantly different among men and
women. Abnormal triglycerides were more prevalent
among men, and waist circumference (IDF definition)
among women. However, there were no statistically sig-
nificant differences on MetS prevalence based on the
three criteria.
Figure 1 shows that metabolic syndrome by AHA/
NHLBI definition increased with age (P value <0.001) for
men and women (P value= 0.001) on HAART use. How-
ever, among treatment naïve participants it increased with
age (P< 0.001), but it did not vary markedly by sex
(P value= 0.1).
Table 3 shows the adjusted PAR for components of
the MetS by sex. The PAR for waist circumference
explained 80% of the prevalence of AHA/NHLBI defin-
ition among men, while triglycerides accounted for the
highest impact on prevalence of metabolic syndrome
according to all criteria, independently of age, skin color
and HAART use.Table 1 Characteristics of the HIV/AIDS patients [N (%) or me
Overall M
(N=
Age (years) 38.6 ±10.1 39.
Years at school 7.5 ±4.1 8.1
White skin color 692 (55.8) 380
Viral load <50 copies/ml 508 (41.6) 268
CD4 (cels/mm3)
<200 181 (14.8) 99
200-350 295 (24.0) 153
>350 751 (61.2) 368
HAART use 815 (65.7) 420
Protease inhibitor use 468 (37.7) 212
Time since HIV diagnosis (years) 4.9 ±4.2 5.2For women, waist circumference explained at least
80% of prevalence of MetS according the NCEP-ATPIII
or AHA/NHLBI criteria, while for the IDF definition
similar impacts were detected for HDL-C, triglycerides,
and blood pressure components.
Discussion
In this large sample of HIV infected patients, the overall
prevalence of metabolic syndrome, under either class-
ification, was noticeable. The AHA/NHLBI definition
accounted for higher prevalence of MetS than those
observed in the NCEP-ATPIII and IDF, which is in ac-
cordance with lower cutoff and lacking of the obligatory
abnormal waist circumference. The overall prevalence of
most MetS components differed considerably among
men and women, but the overall prevalence did not vary
by sex. Even though the three definitions of MetS were
based on the same components, the cutoffs for waist cir-
cumference differ markedly on NCEP-ATPIII and IDF,
as well as the hierarchy of the central obesity.
This study also estimated the PAR in order to assess
separately the contribution of each component on MetS
prevalence. This approach assumes that the abnormal
MetS components are randomly distributed among the
HIV-infected population, but they might be clustered as a
consequence of HAART, and, therefore, the PAR could be
overestimated. HAART can cause abnormality on lipids
and glucose metabolisms [15,16], but these changes could
also be caused by the HIV infection [28,29]. In order to
minimize the confounding factors, PAR were adjusted for
age, skin color, and HAART use.
This study detected lower prevalence rate of MetS,
by NCEP-ATPIII definition, than previously described
[30-32], which could be attributed to the similar number
of men and women, and to the 66% of subjects on
HAART, versus the dominance of men and HAART use
in those studies. The estimate of MetS based on the IDFan ±SD]
en Women P value
1240) (N = 628) (N=612)
5 ±9.6 37.7 ±10.4 0.003
±4.2 6.8 ±3.8 <0.001
(60.5) 312 (51.0) <0.001





(66.9) 395 (64.5) 0.4
(33.8) 257 (42.0) 0.003
±4.6 4.6 ±3.8 0.01
Table 2 Prevalence of metabolic syndrome and its components according to criteria, by sex [% and (95%CI)]
Overall Men Women P value
(N= 1240) (N = 628) (N=612)
Abnormal waist circumference ǂ 20.9 (18.6-23.2) 8.1 (6.0-10.2) 34.0 (30.2-37.8) <0.001
Abnormal waist circumference ǂǂ 46.4 (43.6-49.2) 34.7 (31.0-38.4) 58.3 (54.4-62.2) <0.001
Blood pressure ≥130/85 mmHg* 28.3 (25.8-30.8) 31.7 (28.1-35.3) 24.8 (21.4-28.2) 0.007
HDL-Cholesterol <40 or <50 mg/dl* 38.8 (36.1-41.5) 33.8 (30.1-37.5) 44.0 (40.1-47.9) <0.001
Triglycerides ≥150 mg/dl* 35.9 (33.2-38.6) 41.8 (37.9-45.7) 29.9 (26.3-33.5) <0.001
Fasting glucose ≥100 mg/d* 15.1 (13.1-17.1) 15.1 (12.3-17.9) 15.0 (12.2-17.8) 0.9
Prevalence of metabolic syndrome
NCEP-ATPIII 17.2 (12.1-22.3) 15.2 (7.9-22.5) 19.2 (12.1-26.3) 0.06
IDF 22.1 (17.2-27.0) 20.7 (13.7-27.7) 23.5 (16,5-30.5) 0.2
AHA/NHLBI 24.7 (19.8-29.5) 24.6 (17.7-31.4) 24.8 (17.9-31.7) 0.9
* Abnormal values or on pharmacological treatment.
ǂCutoffs by sex: NCEP-ATPIII ≥ 102 cm in men, ≥ 88 cm in women.
ǂǂCutoffs by sex: IDF and AHA/NHLBI definition ≥ 90 cm in men, ≥ 80 cm in women as the thresholds for South Americans.
Figure 1 Age distribution of subjects with Metabolic Syndrome according to the AHA/NHLBI (P value <0.001) by sex (P value = 0.001)
among HAART users and naïve participants (P values <0.001 and 0.1, respectively).
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Table 3 PAR† (95%CI) for metabolic syndrome components according to the criteria, by sex
NCEP-ATPIII IDF AHA/NHLBI
Men
Abnormal waist circumference * 33.1 (23.1 - 43.1) 100.0 80.6 (73.3-87.8)
HDL-Cholesterol <40 or <50 mg/dlǂ 65.2 (52.9 - 77.5) 37.9 (25.2 - 50.6) 50.2 (39.6-60.7)
Triglycerides ≥150 mg/dl 88.8 (80.9-96.7) 74.3 (64.7 - 83.9) 79.4 (71.7-87.2)
Fasting glucose ≥100 mg/d 42.6 (31.2 - 53.9) 33.5 (23.9 - 43.2) 37.1 (28.5-45.7)
Blood pressure ≥130/85 mmHg 68.0 (56.5 - 79.6) 55.4 (44.2 - 66.7) 59.2 (49.5-68.9)
Women
Abnormal waist circumference * 80.4 (72.1-88.7) 100.0 89.8 (82.9-96.7)
HDL-Cholesterol <40 or <50 mg/dlǂ 66.7 (55.8-77.6) 60.7 (50.1-71.2) 63.0 (53.1-72.9)
Triglycerides ≥150 mg/dl 64.1 (53.5-74.7) 61.2 (51.7-70.8) 62.2 (53.0-71.4)
Fasting glucose ≥100 mg/d 44.5 (34.5 - 54.4) 38.9 (30.0-47.9) 40.8 (32.3-49.4)
Blood pressure ≥130/85 mmHg 62.6 (52.5-72.8) 57.4 (47.9-66.9) 58.8 (49.7-67.8)
† PAR: Population Attributable Risk adjusted for age, skin color, and HAART use.
* NCEP-ATPIII (National Cholesterol Education Program-Adult Treatment Panel III) ≥ 102 cm in men, ≥ 88 cm in women; IDF (International Diabetes Federation)
and AHA/NHLBI (American Heart Association/National Heart, Lung and Blood Institute) definition ≥ 90 cm in men, ≥ 80 cm in women according the thresholds for
South Americans.
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[13] than other studies, which can be partially explained
by the high lipodystrophy rate detected among Italian
volunteers [33], and the waist circumference cutoffs,
which for Brazilians should be the same as those recom-
mended for the South Asians [4,7].
This study detected high prevalence of MetS for men
and women with abnormal waist circumference by the
IDF and AHA/NHLBI definition. The cutoffs for waist
circumference used for South Asians might be exces-
sively low for Brazilians, but they have been previously
used in different contexts among non HIV-infected
populations [34,35]. The trend for higher prevalence of
metabolic syndrome among women might be related
to their increased prevalence of central obesity, abnor-
mal HDL-cholesterol, and use of protease inhibitors in
comparison with men. Since waist circumference is a
mandatory component of the IDF, its impact on MetS
prevalence was conceivably 100%.
This study detected lower MetS prevalence by IDF
than observed in the general population of Greece
[36,37]. Probably, those differences could be attributed
to the cutoffs for waist circumference that used ethnic
recommendations for abdominal obesity and to lower
mean age of HIV-infected patients, which is directly
related to abdominal obesity [38,39].
The highest impact of triglycerides and waist circumfer-
ence suggest that there are consequences associated with
the MetS definition adopted to implement any preventive
strategy. However, the other components also contributed
to the metabolic syndrome burden, and changing their
status could result on a substantial reduction on MetS
due to triglycerides in males, or waist circumference, in
women. The PAR of MetS components might be used toassess the impact of comorbidities, the need for comorbid-
ities treatment, and the HAART toxicity of specific drugs
[40]. Interventions to face the burden of metabolic syn-
drome as well as to determine the health care priority
among those who needs medical attention and are at risk
for cardiovascular disease are also potential uses for PAR
in this area of knowledge.Conclusions
In conclusion, the increasing number of antiretroviral
agents, longer duration of HAART use, and ageing of
the HIV population, might contribute to the growing
prevalence of metabolic syndrome and to reduce the life
expectancy of HIV-infected patients. This approach of
measuring the impact of MetS components on PAR
might be useful for comparing the effect of interventions
targeting reduction of metabolic syndrome prevalence
among HIV-infected populations.
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